REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the quarter and year ended December 31, 2017, after the market close on Tuesday, February 27. Foamix will host a conference call and webcast at 8:30am Eastern Time on Wednesday, February 28.
|Conference Call & Webcast|
|Wednesday, February 28 @ 8:30am Eastern Time|
|Replays, Available through March 14:|
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
Ilan Hadar, CFO & Country Manager
Foamix Pharmaceuticals Ltd.
US Investor Relations
LifeSci Advisors, LLC